| Description | Lanreotide acetate (BIM 23014 acetate) is a somatostatin analogue with antineoplastic activity, used for carcinoid syndrome |
| In vivo | 在小鼠GH3肿瘤异种移植模型中，lanreotide 10 mg/kg 对GH3肿瘤的生长有中等程度的抑制作用，其肿瘤生长延迟（TGD）时间为4倍，范围从4.5至8.3天。分割的局部肿瘤放射疗法单独显著抑制了肿瘤生长，对于250 cGy分割，产生了35.1+/-5.7天的TGD [1]。 |
| Animal experiments | Animal Model:Male nude mice, 8 weeks old and 20–25?g in body weight (GH3 tumor-bearing nude mice).Dosage: 2.5, 5, 10?mg/kg. Administration:Subcutaneous; daily for 5 days[1] |
| Synonyms | Lanreotide acetate (108736-35-2 free base), BIM 23014 (acetate), BIM 23014 acetate |
| molecular weight | 1156.39 |
| Molecular formula | C56H73N11O12S2 |
| CAS | 2378114-72-6 |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 22.5 mg/mL (19.46 mM) |
| References | 1. Ning S, et al. Lanreotide promotes apoptosis and is not radioprotective in GH3 cells.Endocr Relat Cancer. 2009 Sep;16(3):1045-55. 2. Lo T S , Hammer K D , Zegarra M , et al. Methenamine: a forgotten drug for preventing recurrent urinary tract infection in a multidrug resistance era[J]. Expert Review of Anti Infective Therapy, 2014, 12(5):549-554. |